News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Mary Stutts

Advertisement

Articles by Mary Stutts

Building the Future of Healthcare Leadership: The HBA Advantage

ByMary Stutts
April 1st 2025

Brand Insights - Thought Leadership | Paid Program

Mary Stutts

Equity for Women in Healthcare: 131 Years is Too Long to Wait

ByMary Stutts
November 13th 2023

Closing the gender gap in pharma—and how we get there together.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?

    2

    Teva Enters $900 Million Agreement to Acquire Emalex

    3

    Pharmaceutical Risks in the Strait of Hormuz

    4

    Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market

    5

    Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us